Elravie Premier Ultra Volume-L — HI Technology HA Filler for Deep Volumising (1ml)

Elravie Premier Ultra Volume-L is Humedix’s highest-density monophasic HA filler — 23 mg/mL cross-linked HA + 0.3% lidocaine engineered specifically for deep subcutaneous placement. The most structural variant in the Elravie Premier range. Targets volumetric face correction, cheekbone augmentation, chin contouring, non-surgical rhinoplasty, and significant lip augmentation. Up to 18 months durability with minimal migration.

Elravie Premier Ultra Volume-L Filler is manufactured by Humedix Co. Ltd., a South Korea-based medical device and pharmaceutical company established in 2003. The product is part of the Elravie Premier dermal filler range, which is distributed across multiple international markets. Regulatory status: KFDA registered · CE marked · GMP certified · ISO.

Elravie Premier Ultra Volume-L Filler contains 23 mg/mL of cross-linked hyaluronic acid plus 0.3% (3 mg/mL) premixed lidocaine for injection comfort. The hyaluronic acid is non-animal, produced by bacterial fermentation and cross-linked using Humedix Co. Ltd.’s HI (High molecular Ideal Reticulated Matrix) Technology technology. Phosphate-buffered saline at near-physiological pH carries the gel.

Per Humedix Co. Ltd.’s clinical data, Elravie Premier Ultra Volume-L Filler delivers 12-18 months of correction depending on placement and patient factors. Duration depends on injection depth, dose, anatomical site, patient metabolism, and facial movement intensity. Subcutaneous placement typically delivers the longer end of the duration range.

Elravie Premier Ultra Volume-L Filler is engineered for subcutaneous · supraperiosteal placement. The standard recommended needle is 27G, supplied in the syringe blister pack. Some practitioners prefer a blunt-tip cannula of equivalent gauge for safer placement in highly vascular zones, particularly for deeper subcutaneous work.

Elravie Premier Ultra Volume-L Filler regulatory status: KFDA registered · CE marked · GMP certified · ISO. The product’s KFDA registration in South Korea is the primary regulatory baseline. CE marking and other international approvals enable distribution in the EU and other regulated markets. US FDA status varies — buyers in regulated jurisdictions should verify approval scope before importation and clinical use.

Store Elravie Premier Ultra Volume-L Filler between 2 °C and 25 °C in original packaging, away from direct sunlight. Do not freeze — freezing damages the HA gel structure. Shelf life is typically 24 months from the manufacturing date printed on the box when unopened. Once a syringe is opened, contents must be used immediately. Partial syringes cannot be retained for later use due to sterility risk.

No. Elravie Premier Ultra Volume-L Filler uses non-animal hyaluronic acid produced by bacterial fermentation — the standard manufacturing approach for modern HA dermal fillers. The product contains no animal proteins or by-products, making it suitable for patients who avoid animal-derived medical products. The product is contraindicated in patients with severe allergies to gram-positive bacterial proteins (used in HA fermentation).

Yes — layered protocols combining different fillers are standard aesthetic practice. Elravie Premier Ultra Volume-L Filler can be combined with other Korean or international HA fillers, neuromodulators (botulinum toxin), or biostimulators (PLLA, calcium hydroxylapatite) within a single session. Always wait the recommended interval between different injectable products and confirm biocompatibility per each manufacturer’s IFU.

Within the Elravie Premier range — Light-L (superficial) → Deep Line LC (mid-deep) → Ultra Volume-L (deepest) — Ultra Volume-L is engineered with the most pronounced HI Technology cross-linking density. The high-density reticulated matrix produces a firm, cohesive gel optimised for subcutaneous and supraperiosteal placement where structural projection is required (cheekbones, chin, nose, jawline). Placing Ultra Volume-L in the superficial dermis would risk visible lumps; placing Light-L in deep subcutaneous would dissipate too quickly to maintain projection.